Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Bruggmann, Philip; Blach, Sarah; Deltenre, Pierre; Fehr, Jan; Kouyos, Roger; Lavanchy, Daniel; Müllhaupt, Beat; Rauch, Andri; Razavi, Homie; Schmid, Patrick; Semela, David; Stoeckle, Marcel; Negro, Francesco

doi:10.4414/smw.2017.14543

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Authors		Bruggmann, Philip Blach, Sarah Deltenre, Pierre Fehr, Jan Kouyos, Roger Lavanchy, Daniel Müllhaupt, Beat Rauch, Andri Razavi, Homie Schmid, Patrick Semela, David Stoeckle, Marcel Negro, Francesco show all authors [1 - 13]
Published in		Swiss Medical Weekly. 2017, vol. 147, w14543
Abstract		In Switzerland, the prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) has been decreasing owing to active harm reduction efforts and an aging population. Recent advances in HCV therapeutics may provide an opportunity to direct treatment to high-risk populations, with a goal of reducing HCV prevalence and preventing new infections. In order to guide these efforts, the current project was undertaken with the following aims: (1) to develop a simple model to estimate the number of new HCV infections using available data on PWID; (2) to examine the impact of intervention strategies (prevention and treatment) on new and total HCV infections among PWID.
Identifiers		DOI: 10.4414/smw.2017.14543 PMID: 29120012
Full text		Article (Published version) (1.4 MB) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie
Research group		Etudes et traitement de l'hépatite C et B (554)
Citation (ISO format)		BRUGGMANN, Philip et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. In: Swiss Medical Weekly, 2017, vol. 147, p. w14543. doi: 10.4414/smw.2017.14543 https://archive-ouverte.unige.ch/unige:106613